Effects of experimental hyperlipidemia and Apo-B conjugate administration on blood tissue factor level and the tissue factor activity of liver

Abstract

Objective: Hyperlipidemia and hypercoagulation are the major risk factors in atherosclerotic events. Low density lipoproteins (LDLs) are the main source of lipids in the athresclerotic plaques within the foam cells. Apoprotein B-100 (Apo-B) is the main protein in the LDL-cholesterol (LDL-C). For this purpose we aimed to investigate blood tissue factor (TF) levels and the TF activity of liver in experimental hyperlipidemia with and without Apo-B conjugate administration. Methods: Thirty two C57BL/6 mice were divided into 3 groups as control group (n=8), hyperlipidemic group (n=8), hyperlipidemic+Apo-B group (n=8). Mice were sacrified at the end of two months and blood lipid parameters, blood TF levels and TF activity of liver were investigated. Serum lipid parameters were determined by using commercial kits, blood TF levels were determined by Elisa and liver TF activities were measured by Quick method. Results: Serum levels of total lipid, cholesterol, LDL-C significantly increased in hyperlipidemic group; LDL-C significantly decreased in both Apo-B and LDL conjugate given hyperlipidemic groups. Serum TF increased significantly in short term hyperlipidemia, TF activities in the liver homogenate also increased significantly. There was no effect of Apo-B conjugates on TF values in blood and liver homogenate. Conclusion: Based on the results of this study Apo-B conjugate administration was effective in hyperlipidemia and hypercoagulation which are important factors in atherosclerosis. On the other hand we believe that new studies are necessary to investigate immunological properties of Apo-B conjugate administration.